Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
30. Januar 2025 08:00 ET
|
Jupiter Neurosciences, Inc.
Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented...
[Latest] Global Clinical Trial Outsourcing Market Size/Share Worth USD 91,210.1 Million by 2033 at a 7.46% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
15. Januar 2025 08:10 ET
|
Custom Market Insights
Austin, TX, USA, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Clinical Trial Outsourcing Market Size, Trends and Insights By Services...
YPrime’s Karl McEvoy Appointed as eCOA Consortium Industry Co-Director for 2025
14. Januar 2025 08:00 ET
|
Y-Prime, LLC
YPrime's Dr. Karl McEvoy, VP eCOA & Patient Technologies, has been appointed Industry Co-Director of the Critical Path Institute (C-Path) eCOA Consortium
Franklin Access (Formerly Franklin Wireless) Successfully Defends Shareholder Litigation
24. Dezember 2024 13:00 ET
|
Franklin Wireless Corporation
SAN DIEGO, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Franklin Access is pleased to announce a significant legal victory in its shareholder litigation, “In re Franklin Wireless Corp. Derivative Litigation”,...
BIOA BREAKING NEWS: BFA Law Announces an Investigation into BioAge Labs, Inc. after Stock Plummets 76% -- Contact the Firm if You Lost Money (NASDAQ:BIOA)
10. Dezember 2024 12:49 ET
|
Bleichmar Fonti & Auld
BioAge Labs, Inc. investors that lost money are encouraged to contact BFA Law about its securities fraud investigation into the Company.
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
19. November 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Legendary Attorney Glenn Zeitz Launches Podcast: Philly Trial Lawyer Stories
24. Oktober 2024 10:00 ET
|
Glenn Zeitz
PHILADELPHIA, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Philly Trial Lawyer Stories, a new podcast from legendary attorney Glenn Zeitz, is set to launch on October 23rd offering listeners an exclusive,...
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
30. September 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
11. Juli 2024 07:00 ET
|
OKYO Pharma LTD
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
10. Juli 2024 07:00 ET
|
OKYO Pharma LTD
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease...